SAN FRANCISCO (Reuters)—A year and a half after the Affordable Care Act brought widespread reforms to the U.S. healthcare system, Chicago’s Cook County Health & Hospitals System has made its first profit in 180 years. Seven hundred miles south, the fortunes of Atlanta’s primary public hospital, Grady Health System, haven’t improved, and it remains as…
On Research Review Boards, Conflict-of-Interest Reporting Improves
(Reuters Health)—Many doctors who serve on hospital panels overseeing the ethics and safety of human research trials have industry relationships that may compromise their objectivity, but reporting these conflicts has become more common over the past 10 years, according to a new study. Physicians who serve on so-called institutional review boards (IRBs) may also be…
How to Launch Successful Rheumatology Patient Advocacy Programs
Editor’s note: This is the second installment of a two-part series showing how a busy office-based practice can incorporate patient advocacy into its standard workflow. In Part 1, we looked at the reasons for incorporating patient advocacy into your practice and offered an outline for implementing it. Part 2 amplifies the concepts explored in Part…
The ACR, Rheumatology Research Foundation Address Research Funding Shortfall
I have spent my entire academic career as a clinical investigator and have grown to recognize the importance of a strong and vibrant rheumatology workforce. However, I am deeply concerned about our ability as a subspecialty to sustain our research enterprise and take advantage of the modern breakthroughs in science. The reduction in federal funding…
The ACR’s State-of-the-Art Clinical Symposium: Experts Discuss Jakinibs, Osteoarthritis, Membranous Lupus Nephritis
CHICAGO—With the approval of the Jak inhibitors (i.e., jakinibs) tofacitinib and ruxolitinib—and others being investigated—rheumatologists need to arm themselves with an understanding of these drugs so they can think critically when evaluating them and deciding how to use them, said John O’Shea, MD, chief of the Molecular Immunology and Inflammation Branch of and scientific director…
The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
CHICAGO—Stem cell transplantation for systemic sclerosis patients has come a long way over the past decade, with more finely calibrated dosing and better patient selection, said George Georges, MD, associate member of the Fred Hutchinson Cancer Research Center and associate professor in the medical oncology division at the University of Washington School of Medicine, Seattle,…
The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy
CHICAGO—Scleroderma patients with pulmonary arterial hypertension (PAH) might benefit from more aggressive therapy, an expert in the field said in a session on lung involvement in rheumatic diseases at the American College of Rheumatology’s 2015 State-of-the-Art Clinical Symposium in May. Newer trials—the SERAPHIN trial on macitentan, GRIPHON on selexipag, and AMBITION on an ambrisentan/tadalafil combination—show…
Rheumatologist Alain Alvarez, MD, Brings Passion for Dance to Medical Practice
There can be a rhythm to rheumatology. At least that’s what Alain Alvarez, MD, can sometimes find. Listening, assessing, helping. It can be a successful dance when doctor and patient become partners, hoping to lead each other forward. When you consider this, it might be little surprise that Dr. Alvarez is also a dance teacher….
Rheumatologists on the Move, July 2015
Arthritis Center Renamed to Honor Ephraim P. Engleman, MD Ephraim P. Engleman, MD, has been on the faculty at the University of California, San Francisco (UCSF) since 1947, 10 years after he received his MD from Columbia University. The 104-year-old rheumatologist is currently the director of the Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, which…
The ACR Partners with Coalition, Patient Advocacy Groups to Advocate for Rheumatology
In terms of getting our message heard in Washington, D.C., rheumatology faces a David vs. Goliath battle on several levels. Many industries have far greater resources, use multiple lobbying firms, and have advertising and lobbying budgets that eclipse ours by several hundred-fold. Rheumatology is far smaller than most other medical specialties; our membership is a…
- « Previous Page
- 1
- …
- 98
- 99
- 100
- 101
- 102
- …
- 151
- Next Page »